Noble

In 2019, became the fourth to be approved by the US FDA. Today, Organon touches on the importance of speed to market for the product.

Organon CEO pins high hopes on upcoming Humira biosimilar launch What’s in store for Merck spinout Organon’s second year? | What’s in store for Merck spinout Organon’s second year? Growth ambitions for birth control implant Nexplanon, plus tuned up sales expectations for its biosimilars and fertility businesses.

Did you know Noble offers full-service in-house design, photography and videography services for clients? Introducing our very own Noble Studios, a one-stop-shop for all your digital and visual needs including step-by-step training videos… right from our Orlando offices.

Noble is Excited to Announce Expansion of Service Offerings for Clients with the Addition of Noble Studios - Noble When Noble broke into the training device market many years ago, we quickly realized how much work there was to be done to help pharma partners achieve their goals for... Read More »

Why do we at Noble devote ourselves to supporting patients who self-administer drug therapies at home? Because research and studies show us they need more support:

Need for Patient and HCP Training - Noble Considerable Gaps Exist in Patient Training and Preparedness for Self-Injected Biologics and Self-Administered Nasal Therapies Millions of patients around the world rely heavily on self-injectable biologics and self-administered nasal therapies to... Read More »

Noble is looking to fill three positions in its Orlando headquarters. Please take a look and feel free to share with anyone you think would be interested. https://www.gonoble.com/careers/

Noble penned a piece in Drug Delivery News shedding light on the ongoing need for around to reduce negative transfer and other gaps for patients.

Noble can help patients reduce errors when self-administering biosimilar therapies - Drug Delivery Business Noble can help patients reduce errors when self-administering biosimilar therapies - Drug Delivery Business

Ford Motor Company recently shared the success it had converting 100% of health maintenance organization utilizers of brand drug Remicade (infliximab) to the Inflectra "with no disruption to patients and no negative feedback from its members."

Michigan Trade Group Outlines Best Practices for Biosimilar Adoption Ford Motor saved $5 million by switching patients to 5 biosimilars, and other manufacturers and employers in Michigan have achieved good results with switching programs, the Economic Alliance of Michigan reports.

Concerned about patient access to monoclonal antibody medications, like , patient groups in India appealed to the country’s executive administration to spur reforms in regulation. http://ow.ly/CtGG50HIe5q